200 stories found
A man in Spain who struggled with severe alcohol dependence credits a weekly GLP-1 injection for significantly reducing his consumption, marking the first public account of this off-label use in the country.
Health insurers are scaling back coverage for popular GLP-1 weight-loss and diabetes medications, while the FDA's recent regulatory moves provide Eli Lilly with a significant competitive advantage in the market.
Financial commentator Jim Cramer identifies a lesser-known pharmaceutical candidate poised to capture significant market share alongside established leaders like Eli Lilly in the rapidly expanding weight-loss drug sector.
Research indicates that patients using GLP-1 receptor agonists for diabetes and obesity face a higher risk of hair loss compared to users of other medications.
Experts propose that integrating weight-loss and metabolic GLP-1 drugs with generative AI tools could drastically lower medical expenses and improve treatment accessibility.
A feature examines the use of GLP-1 drugs among diverse individuals, including a body positivity advocate and a scientist, reflecting the broader societal shift and medical adoption of these weight-management treatments.
A new Medicare pilot program aims to lower GLP-1 medication costs to $50 monthly for some seniors, but eligibility restrictions mean many patients with severe conditions will not qualify for the discount.
A new episode of the Reuters podcast features discussions on geopolitical developments in Nepal, economic shifts related to the Federal Reserve, and the growing cultural impact of GLP-1 weight loss drugs.
The parent company of medical device manufacturer Nemera is considering selling the firm as global demand for weight-loss drug delivery systems continues to accelerate, boosting valuation prospects.
Market data reveals that Canadian consumers spent $2.4 billion on GLP-1 drugs in the first half of 2026, reflecting sustained high demand for weight-management and diabetes treatments.
Medical professionals emphasize the importance of consistent exercise and improved nutrition, while noting that GLP-1 medications may also be considered as part of a long-term weight loss strategy.
Innovent Biologics released earnings data highlighting robust revenue from GLP-1 drugs and announced ambitious revenue projections for 2030, prompting a 15% upward revision in fair value estimates.
Financial analysts identify two publicly traded companies positioned to benefit from the rapid expansion of the GLP-1 receptor agonist market for weight loss and diabetes treatments.
Industry analysis highlights Eli Lilly's strategic advantages over rival Novo Nordisk in the rapidly expanding obesity treatment sector, positioning the pharmaceutical giant as the primary beneficiary of the GLP-1 gold rush.
A new report reveals a growing interest in drink choices among restaurant customers. The report found that health is already influencing some Americans' decisions about alcohol.
Financial analysts question whether the GLP-1 weight-loss medication sector is truly a winner-take-all duopoly or if broader market dynamics favor multiple competitors.
New studies suggest that GLP-1 medications, typically used for diabetes and weight loss, may have an unexpected side effect of helping individuals with various addictions.
CoreageRx has launched four new supplements aimed at muscle, digestion, and GLP-1 support, alongside advanced preventive longevity protocols. These new offerings include microdosing Semaglutide, Tirzepatide, and Sermorelin therapies.
GLP-1 drugs are being hailed as a potential 'game-changer' for America's obesity crisis, but their widespread impact is hindered by two significant inequalities. These disparities limit access and effectiveness for many who could benefit.
Messages about GLP-1 weight-loss drugs are reportedly flooding social media applications, raising concerns about their potential negative impact on teenagers' perceptions of health and body image.
Large food companies are grappling with a significant challenge as GLP-1 drugs threaten billions in sales, prompting them to explore new strategies to appeal to consumers with reduced appetites.
This article discusses five food stocks, including Smucker and Pepsi, that are recommended for purchase, detailing how they can potentially defy concerns related to GLP-1 drugs.
An Illinois man, Rodney Greer, has been accused by prosecutors of impersonating doctors to secure unauthorized prescriptions for GLP-1 drugs like Ozempic and then selling them to customers.
Amylyx Pharmaceuticals has announced successful results from a late-stage clinical trial for its GLP-1 drug.
Parents using GLP-1s are advised to consider the impact of their body changes on children, as bullying can also cause significant stress for parents.
Actress Chrissy Metz has responded to online critics commenting on her body, revealing that her father's death from obesity complications led her to start GLP-1 medication.
GLP-1 drugs are showing significant promise in treating a hormonal disorder that causes constant weight gain and forces women to shave facial hair. Patients describe the drugs as a 'godsend' for managing symptoms.
Analysis suggests that only individuals earning nearly £100,000 annually can make overall savings on food bills after accounting for the £1,200 cost of GLP-1 weight-loss medications, effectively making them a 'regressive tax on being thin'.
A report indicates that a teenager has died from an irregular heartbeat following the use of a GLP-1 medication.
Professionals in various fields are facing increased pressure regarding their physical appearance due to the rise of GLP-1 medications and cosmetic surgeries, influencing job perceptions.
GLP-1s are known for weight loss. A physician reviews 7 evidence-backed benefits, from kidney and liver disease to sleep apnea, addiction, clots and cancer progression.
GLP-1 medications like Ozempic and Wegovy are being studied for their potential beyond weight loss, specifically their ability to reduce cravings for alcohol and other addictive substances by affecting a specific brain region.
AstraZeneca's Chief Financial Officer provides insights on the company's strategy regarding GLP-1 drugs, artificial intelligence, and other key business areas.
Eli Lilly has significantly raised its revenue and profit outlook for 2026, driven by soaring demand for its obesity drugs Mounjaro and Zepbound, which are widening its lead over competitor Novo Nordisk. This surge in sales highlights the booming market for GLP-1 weight-loss medications.
Bank of America is reportedly spending $250 million per year on GLP-1 weight loss drugs for its employees. This significant expenditure reflects the growing adoption and cost of these medications.
CVS Health is expanding its GLP-1 (glucagon-like peptide-1) offerings through a new partnership with Lilly. This collaboration aims to enhance access to and management of medications for conditions like diabetes and weight loss.
A breast cancer surgeon suggests that popular GLP-1 weight-loss drugs like Ozempic and Wegovy may help lower the risk of cancer recurrence by reducing BMI, estrogen levels, and inflammation.
The European Commission has approved Wegovy in tablet form, making it the first oral GLP-1 receptor agonist for treating obesity and overweight in EU countries, previously only available as an injectable.
Supermodel Heidi Klum was photographed on a yacht in St. Barts with her daughter, weeks after she revealed her husband's advice to 'eat more' and her personal decision to refuse GLP-1 weight loss medications.
A new study indicates that GLP-1 drugs, commonly used for diabetes and weight loss, could potentially be personalized for individuals, tailoring treatments to specific patient needs.
A new study suggests that GLP-1 pills may be effective in helping adults with alcohol problems reduce heavy drinking, offering a potential new treatment for the condition.
Altimmune's stock increased following positive results from its mid-stage trial for a GLP-1 drug, which showed a reduction in alcohol consumption.
FedEx is expanding its business-to-business healthcare shipping services, identifying it as a key vertical to bolster its operations, particularly in response to the growing GLP-1 market.
Leading endocrinologists are recommending that diet become a standard part of care when prescribing GLP-1 weight loss drugs for patients in India.
Shipping and logistics companies are increasingly focusing on the expanding healthcare market, with a particular emphasis on developing cold chain and temperature-controlled facilities to meet the demands of new drugs like GLP-1s.
Australia's Therapeutic Goods Administration (TGA) has issued a warning about a 'rare but severe' eye disorder, Non-Arteritic Ischemic Optic Neuropathy (NAION), linked to GLP-1 drugs such as Ozempic, updating product information for these medications.
A new study suggests a link between GLP-1 weight loss and diabetes medications, such as Ozempic, and an increased risk of hair loss, though this side effect is considered rare.
Novo Nordisk, maker of Ozempic, has filed a lawsuit against rival pharmaceutical company Eli Lilly, alleging that its advertising for weight-loss drugs is misleading, intensifying competition in the rapidly growing anti-obesity medication market.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging misleading advertising claims related to GLP-1 medications.
Cathie Wood's ARK Invest has been actively adjusting its portfolio, including increasing its stake in a high-performing GLP-1 stock and purchasing $51 million worth of SpaceX shares after a significant price drop. Conversely, ARK has also been selling shares of another high-flying stock.
A new study indicates that weight-loss drugs, specifically GLP-1s, could be beneficial for children as young as six years old, potentially also easing pressure on health services.
Recent changes in insurance coverage for GLP-1 medications are impacting millions of Americans, prompting questions about eligibility and how to determine coverage.
GLP-1s (Glucagon-like peptide-1s) are being studied for their effects on energy levels and fatigue. Research indicates that these compounds can influence how the body manages energy, potentially offering insights into combating tiredness.
Fractyl experienced gains following news that its Revita procedure effectively reduces weight gain in individuals who have previously used GLP-1 medications. This development highlights the procedure's potential in post-GLP-1 weight management.
A new study emphasizes the importance of monitoring frailty risks when older adults use GLP-1 drugs, suggesting potential concerns for this demographic.
New research suggests that GLP-1 receptor agonists, drugs typically used for type 2 diabetes and obesity, may possess anti-inflammatory properties beneficial for patients with dermatological diseases. This finding comes from a summary of current knowledge on their application in dermatology.
Social media and GLP-1 medications are driving increased interest in hydration products, leading companies to invest in new offerings like electrolyte mixes and 'hydrating hot chocolate'.
Investment advice for July highlights dividend stocks like Altria for passive income and high-growth GLP-1 biotech winners. The recommendations focus on strategic buys for both immediate payouts and long-term growth potential.
Dr. Mehmet Oz emphasizes the link between obesity and the rise in chronic diseases, supporting GLP-1 weight loss medications as a 'jumpstart' while stressing the continued importance of diet and exercise.
A survey reveals that employers are not significantly expanding coverage for GLP-1 obesity drugs, with many finding alternative ways to manage costs.
Kailera's shares experienced a decline after the release of late-stage trial data for its oral GLP-1 candidate. The specific details of the trial data and the extent of the stock drop were not immediately clear.
A Texas principal, Gerardo Moreno Mendez, was arrested last month and faces charges for allegedly selling GLP-1 drugs to school staff, having been hired by a second school district prior to his arrest.
A new pilot program will allow millions of Medicare beneficiaries to access GLP-1 medications for obesity treatment with a monthly copay of $50, marking the first time such coverage is provided.
A new Medicare pilot program offering GLP-1 drugs for $50 to some adults aged 65 and above has raised concerns about potential drug shortages.
GLP-1 medications have transformed weight loss, but their appetite-suppressing effects can lead to reduced food intake. Experts suggest specific supplements to address potential nutritional gaps.
A new oral GLP-1 pill has demonstrated nearly 12 percent weight loss over 36 weeks in a recent study. Experts are also cautioning about potential risks of GLP-1 weight loss drugs for women in menopause.
Analysts suggest that exaggerated fears surrounding weight-loss drugs and a recent onboarding error have created a buying opportunity for long-term investors in a specific medical device company.
The Trump administration’s initiative to expand GLP-1 weight loss medication coverage under Medicaid has faced limited uptake, with only Indiana formally joining the pilot program so far.
Readers discuss the potential adoption of alternative oral formulations of GLP-1 medications as pharmaceutical companies develop more convenient delivery methods for weight management.
As GLP-1-based therapies reshape weight management, brands are looking beyond appetite control to nutrition quality, ...
The widespread adoption of GLP-1 medications is reigniting societal pressure to maintain thinness, challenging recent body positivity movements and altering cultural perceptions of attractiveness.
Shares of Victoria's Secret have jumped nearly 300% as the growing popularity of GLP-1 weight-loss medications alters consumer shopping habits and boosts the brand's financial outlook.
The digital health platform specializing in prescription weight-loss medications has achieved third-party verification, reinforcing its compliance with industry safety and ethical standards.
Employer-sponsored health plans have reduced coverage for GLP-1 medications from 72% to 60%, raising concerns that rising pharmaceutical costs and utilization rates are creating barriers to access for patients.
Despite monthly prices dropping to around $14, GLP-1 medications face sluggish demand in India due to cultural stigma and cautious prescribing practices among physicians.
Deutsche Bank has downgraded Novo Nordisk shares to a Sell rating after the pharmaceutical giant reported quarterly earnings, citing stretched valuations rather than concerns over its weight-loss drugs. The downgrade contributed to a decline in the company's stock price.
National obesity statistics show a historic downturn coinciding with the widespread adoption of GLP-1 weight-loss medications like Ozempic, signaling a major shift in public health trends.
Analysis suggests Hims & Hers Health could capitalize on the expanding GLP-1 weight-loss medication market through direct-to-consumer sales and telehealth integration.
The beverage and snack giant announced it will stop covering certain GLP-1 weight-loss drugs in its employee health plans, citing unsustainable premium increases and overall cost pressures.
The surge in demand for GLP-1 drugs like Ozempic has driven interest in psyllium husk, though experts question whether it can truly replicate prescription weight-loss results.
A report by IFF indicates that GLP-1 is significantly altering food choices and eating behaviors among consumers in India.
IMAGE Skincare is expanding its GLP-1-targeted skincare line with the introduction of a new VOL.U.LIFT™ BODY Sculpt + Firm Treatment Complex.
Researchers at UC Berkeley have identified a potential new treatment for obesity and diabetes that works by boosting internal metabolism, offering a different mechanism compared to GLP-1 drugs like Ozempic and Mounjaro.
A Wells Fargo report indicates that the increasing use of GLP-1 medications has led to a more than 30% reduction in bariatric surgery rates, offering a pharmaceutical alternative for weight management.
GLP-1 drugs are being hailed as a potential 'game-changer' for America's obesity crisis, but two significant inequalities are hindering their widespread impact and economic viability, according to industry experts.
A breast surgical oncologist outlines five daily strategies that may help reduce cancer risk and improve outcomes, including the potential role of GLP-1 drugs like Ozempic.
Half of Hollywood is reportedly using a 'medicine that cannot be named' (likely a GLP-1 agonist like Ozempic or Wegovy), indicating a significant trend in the entertainment industry.
Pharmaceutical companies are actively developing a new generation of GLP-1 medicines for weight loss, aiming to create drugs with fewer side effects as some existing patents begin to expire.
The CEO of Hims has responded to a lawsuit from the FTC and anticipates that prices for GLP-1 drugs will fall to $40-$50, according to CNBC.
Nestlé is developing new products specifically for consumers using GLP-1 weight-loss medications, aiming to tap into a potentially lucrative market. The company sees a billion-dollar opportunity in catering to the dietary needs of individuals on these drugs.
An investment analysis identifies two GLP-1 stocks with the potential to double in value by the year 2031.
A nutritionist provides recommendations for 15 specific foods for individuals using GLP-1 medications, emphasizing careful nutrient intake due to reduced appetite.
Celebrities like Chrissy Metz and Serena Williams are among those discussing the use of GLP-1 weight loss injectables such as Ozempic, Mounjaro, and Wegovy, highlighting the public's growing engagement with these medications.
The CEO of Cava, a major restaurant chain, stated that GLP-1 weight-loss drugs are contributing to the emergence of a 'big kids' market, with diners increasingly opting for kids' meals.
The competitive landscape between Eli Lilly and Novo Nordisk is increasingly defined by their manufacturing capabilities for GLP-1 drugs.
GLP-1 medications such as Ozempic and Wegovy are being studied for their potential beyond weight loss, specifically their ability to reduce cravings for alcohol and other addictive substances. Some users of these drugs have reported that their desire for alcohol disappeared or that they experienced nausea when drinking.
Starbucks will cease covering GLP-1 drugs prescribed for weight loss for its benefits-eligible employees starting in October, citing rising employer healthcare costs.
Amazon is expanding its healthcare offerings by planning to provide GLP-1 weight-loss drugs to patients covered by Medicare Part D.
Eli Lilly's stock experienced a significant jump following strong GLP-1 sales, further widening its lead over competitor Novo Nordisk.
A company, identified as a supplier of proprietary packaging, is highlighted for its potential to boost share price by benefiting from the overall growth of the GLP-1 drug industry, rather than betting on a single pharmaceutical winner.
Novo Nordisk has increased its earnings forecasts for 2026, attributing the upward revision to strong sales of its Wegovy pill. The company's GLP-1 sales have soared, leading to a boost in its financial outlook.
The effectiveness of natural GLP-1 alternatives to traditional weight-loss drugs is gaining attention, prompting questions about their actual impact and benefits.
PODCAST: Iran pause, Moscow restaurant attack and GLP-1 clothes shopping Reuters
Medicare patients are gaining access to GLP-1 medications for obesity through the new Bridge program, but the initiative is proving complex due to unclear eligibility, prior authorization requirements, and cost concerns.
Canada's largest grocer, Loblaw, reported increased profits driven by sales of generic GLP-1 drugs, which are up 40% year-to-date, and a rise in bargain-hunting shoppers.
An individual shares personal insights and tips on how taking a GLP-1 medication has changed their approach to planning and experiencing travel, shifting focus away from food and drink.
The Guardian is seeking input from readers who have used GLP-1 drugs such as Wegovy and Mounjaro for weight loss but have not experienced the desired effects, acknowledging that these drugs are ineffective for a small percentage of users.
The Centers for Medicare and Medicaid Services have introduced the Medicare GLP-1 Bridge, a demonstration program offering eligible beneficiaries access to certain anti-obesity medicines for $50 a month.
Experts explain that individuals typically regain lost weight after discontinuing GLP-1 medications used for weight loss. Strategies to prevent this effect are being discussed.
US forces reportedly fired upon a vessel in the Gulf of Oman, an incident that led the EU to delay the release of satellite imagery of the area at the request of the US. This event unfolds amidst broader regional tensions and reports of China pushing for renewed US-Iran talks.
The GLP-1 paradox highlights the challenge of these highly effective drugs being too expensive for widespread coverage, yet too beneficial to be overlooked in healthcare.
The increasing popularity of GLP-1 weight-loss drugs, such as Ozempic, is significantly altering consumer spending habits and forcing major industries to adapt to these shifts in the economy.
Financial analyst Jim Cramer has reiterated his support for Eli Lilly, even as the pharmaceutical company faces a GLP-1 lawsuit from a rival, explaining his reasons to investors.
A woman taking a GLP-1 medication experienced a stomach mass dissolving with the help of Diet Coke.
A doctor explains how modern science has moved beyond the 'eat less, move more' myth, reshaping the understanding of obesity as more than a willpower failure, and highlights the life-changing potential of new GLP-1 treatments.
Henry Gonzalez, founder of a San Francisco clothing brand, successfully lost nearly 350 pounds without surgical intervention or GLP-1 medications, attributing his transformation to wall pushups and a trainer.
Startups are currently testing GLP-1 treatments for overweight cats, while major pet-food companies are focusing on longevity products, reflecting a growing trend of owners spending more on animal health.
Intuitive Surgical's stock has dropped as changes to the Affordable Care Act (ACA) and the impact of GLP-1 drugs weigh on the company's growth prospects.
Neurologists are warning that GLP-1 weight-loss drugs like semaglutide (Ozempic, Wegovy) may accelerate the progression of ALS by triggering dangerous rapid weight loss in patients with brain disorders.
The widespread use of GLP-1 drugs like Ozempic is causing disruptions in the wedding dress industry, as bridal designers adapt to accommodate rapid weight loss among customers.
Amidst a surge in GLP-1 medication use and social media trends, an article investigates which viral solutions for facial volume loss are actually effective.
An article explores the reasons why GLP-1 weight-loss medications, despite their impressive success rates, may not be effective for all individuals.
Users of GLP-1 weight-loss medications in the UK and US are significantly altering their spending habits and wardrobes as they slim down, creating a 'new consumer' trend in clothes shopping.
China has expanded its essential medicine list by including a second GLP-1 diabetes drug. This move aims to improve access and affordability for patients managing diabetes across the country.
A BMJ study suggests that weight loss drugs offer limited heart health benefits in their first year of use, prompting experts to caution that it is too soon for a final verdict. The research also decodes the strengths and weaknesses of 19 GLP-1 drugs regarding weight loss, muscle mass, and heart risk.
While Eli Lilly and Novo Nordisk are prominent players in the GLP-1 market, new analysis suggests that other stocks could offer even better investment opportunities in this rapidly growing sector. Investors are exploring broader options within the GLP-1 boom.
A growing number of Indians are using GLP-1 injections like Ozempic for rapid weight loss, primarily influenced by wedding pressures and social media ideals, raising concerns among medical professionals.
Whey, a dairy byproduct, has become a star in the 'proteinmaxxing' boom driven by GLP-1s, leading to such high demand that US producers are struggling to keep up with the once niche supplement.
An analysis explores Medicare's coverage of GLP-1 drugs and its potential implications for the future of the biotechnology sector.
An analysis suggests that older Americans, currently excluded from the expensive GLP-1 drug trend, are anticipated to utilize a new program designed to improve their access to these medications.
Millions of Americans can now get Medicare to cover GLP-1 drugs for weight loss, a significant expansion as previously Medicare only covered these drugs for conditions like Type 2 diabetes, sleep apnea, or stroke/heart-attack risk.
The head of Biocon has issued a warning regarding GLP-1 drugs, while the CEO of Zerodha has highlighted a period of weak market demand.
Contrary to a broader trend of employers scaling back obesity medication benefits, Bank of America continues to offer comprehensive coverage for GLP-1 treatments.
Investment firm Riverwater characterizes the recent surge in Stevanato Group stock as a market overreaction following the commercial rollout of oral GLP-1 diabetes medications.
Rapidly growing prescriptions for GLP-1 medications like Mounjaro are significantly reducing dining frequency, forcing restaurant operators to adapt or risk financial decline.
New findings indicate that GLP-1 medications can produce significant weight loss results when initiated at lower dosages, potentially improving patient tolerance and accessibility.
Pattern hair loss affects an estimated 80 million Americans, yet no new drugs have been approved since the late 1990s, prompting investors to target the untreated therapeutic market.
Biotech company Ascletis has administered the first dose to a participant in its global Phase III clinical trial for ASC30, an experimental oral medication designed for chronic weight management. The milestone advances development of a once-daily GLP-1 receptor agonist alternative to injectable treatments.
Market analysts are redirecting capital toward pharmaceutical developers targeting pattern hair loss, forecasting stronger returns compared to the saturated GLP-1 weight-loss sector.
A recent analysis explores the psychological effects associated with rapid weight loss from GLP-1 receptor agonists, highlighting concerns over mood changes and mental well-being alongside physical results.
Novo Nordisk and Eli Lilly are utilizing court orders and public awareness campaigns to combat the surge of counterfeit GLP-1 medications flooding international markets.
Analysts issue a 'sell' rating for the weight-loss drug maker, citing mounting fears that patent expirations and market saturation will severely impact future earnings.
Biotechnology firm SynbioTech will present its latest research on the TWK10 compound and its microbiome contract development platform, targeting the rapidly expanding market for GLP-1 companion nutrition products.
New Medicare discounts for weight-loss drugs like GLP-1 agonists are facing implementation hurdles, leaving many high-risk patients with obesity and related conditions unable to access the medication.
The food conglomerate aims to replicate its strong performance in Europe's ketchup sector as GLP-1 medications reshape American dietary consumption habits.
Doctors caution that while GLP-1 drugs like Ozempic show lower cancer rates in observational data, healthy-user bias and short follow-up periods mean prevention remains unproven.
Eli Lilly filed a lawsuit targeting six pharmaceutical companies for allegedly marketing unapproved weight-loss drugs, positioning itself to maintain dominance in the competitive GLP-1 market alongside rival Novo Nordisk.
A new daily pill designed to treat diabetes and aid in weight loss is now available in UK pharmacies via private prescription, though pharmacists have warned about the potential for counterfeit GLP-1 medications.
CoreAge Rx has launched new weight reset coaching and education programs, expanding its weight and metabolic health offerings. These programs aim to maximize patient success with affordable, doctor-guided GLP-1 medications like Semaglutide and Tirzepatide.
A new analysis of a US adverse event database suggests GLP-1 weight-loss drugs are associated with changes in women that were not tracked during clinical trials, beyond their known digestive side effects.
Fashion brands are reportedly scaling back their plus-size clothing ranges in the US, a trend linked to the increasing popularity of GLP-1 weight-loss drugs.
A discussion explores whether the supplement berberine, known for glycemic control, lives up to its comparison with GLP-1 analog medications like Ozempic, or if its efficacy is overstated by marketing.
Hershey is exploring ways to adapt its Halloween candy offerings to align with evolving weight-loss trends and a growing focus on health, influenced by factors like GLP-1 drugs.
Amylyx Pharmaceuticals' stock (AMLX) surged following the successful outcome of a late-stage trial for its GLP-1 drug.
Amylyx stock experienced a significant 55% surge following the announcement that its GLP-1 blocker successfully met all trial goals.
As millions use GLP-1 weight-loss medications, Nestlé sees an opportunity to develop products that can help manage the challenges associated with these drugs.
Three nutrition specialists discussed effective ways to reduce belly fat, noting that the recent focus on GLP-1 agonists for weight loss and diabetes treatment has intensified discussions around the topic.
An investment analysis identifies two GLP-1 (Glucagon-like peptide-1) stocks that are projected to potentially double in value by the year 2031.
AstraZeneca states that the market for GLP-1 drugs extends beyond just weight loss, indicating potential for these medications in treating other conditions.
Hims & Hers (HIMS) has raised its guidance, prompting questions about whether its growth can be sustained following a margin reset related to GLP-1 treatments.
Actress Chrissy Metz, known for 'This Is Us,' has revealed she turned to a GLP-1 drug for her health, overcoming initial nervousness and skepticism, and is now focusing on longevity and overall well-being.
Actress Chrissy Metz shared her decision to start using GLP-1s for her weight loss journey, after initially being skeptical about the type 2 diabetes medication.
An analysis compares Eli Lilly and Viking Therapeutics to determine which company offers a better investment opportunity in GLP-1 stocks.
Pharmaceutical giants Eli Lilly and Novo Nordisk have successfully defeated an antitrust lawsuit concerning their market position in GLP-1 drugs.
More than 150 deaths have been reported in connection with the use of GLP-1 weight loss drugs, with most complaints concerning gastrointestinal reactions.
Bank of America's CEO has revealed that the company spends more than $250 million annually on GLP-1 drugs for its employees. This significant expenditure highlights the growing use of these medications within corporate health benefits.
In Brazilian supermarkets, GLP-1 medications like Ozempic are influencing consumer habits, leading to a reorganization of aisles where traditional items like pão de queijo are losing shelf space to healthier options like yogurt.
Research continues to reveal less-known side effects of GLP-1 weight-loss drugs like Ozempic and Wegovy, beyond common issues like nausea, with new findings highlighting potential impacts on kidney function, hair loss, and menstrual changes.
Miles Harrison, CEO of Conexeu Sciences, participated in a fireside chat to discuss the emerging GLP-1 market, which is projected to reach billion-dollar valuations.
The increasing use of GLP-1 drugs is reportedly influencing consumer behavior, leading to a resurgence in in-store clothes shopping among users.
As Americans increasingly obtain GLP-1 weight-loss drug prescriptions directly, major retail pharmacy chains like Walmart, Costco, and Amazon are expected to see significant gains.
The European Commission has approved Wegovy in tablet form as the first oral GLP-1 receptor agonist for the treatment of obesity and overweight in EU countries, marking a breakthrough in pharmacological tools against obesity.
Eli Lilly has committed $2.8 billion to a new venture, signaling a strategic move to expand its portfolio beyond its highly successful GLP-1 drugs.
The necessity for GLP-1 drugs to remain cold is emerging as a significant growth driver for logistics giants United Parcel Service, Inc. (UPS) and FedEx Corporation (FDX). This requirement creates new opportunities in cold chain logistics.
Doctors are cautioning against a new trend of microdosing GLP-1 weight loss medications, warning that it can reduce their effectiveness and potentially be dangerous.
While GLP-1 medications are widely used for weight loss, doctors are now exploring their less understood, unexpected impacts on users' romantic relationships and love lives.
Rapidly popular GLP-1 drugs, used for weight loss and diabetes, are now being associated with hair loss, according to a new study. Experts are explaining the potential reasons behind this side effect.
An aesthetics company, a maker of Botox, has reported an increase in demand for treatments addressing facial volume loss, a phenomenon sometimes referred to as 'Ozempic face,' which is linked to the increased use of GLP-1 drugs.
An analysis suggests that GLP-1 weight-loss medications like Wegovy and Mounjaro could significantly decrease the risk of alcohol-related hospital admissions by 26%.
Medicare has introduced a new deal for GLP-1 medications priced at $50, but the article highlights a significant catch that most people tend to overlook. This detail could impact beneficiaries' understanding of the offer.
Citi has raised its target for Novo Nordisk following the strong launch of the company's GLP-1 pill, indicating positive market reception.
A new Greek study suggests that GLP-1 drugs, primarily known for treating obesity and type 2 diabetes, may also be effective in combating alcohol and other addictions. This opens a new field of potential applications for these medications.
A weight-loss specialist suggests that GLP-1 drug results can enhance confidence in job interviews and dating, although a study found no clear improvement in overall well-being.
The potential for microdosing GLP-1 drugs for weight loss is being explored, with medical experts advising that such use should only occur under strict medical supervision.
An analysis suggests that a specific GLP-1 stock has the potential to double in value by 2030, indicating strong growth prospects within the pharmaceutical sector.
The influence of GLP-1 medications is reportedly teaching restaurants new lessons about how to design their menus, potentially in response to changing consumer preferences or dietary needs.
This article discusses ways to improve metabolism and lose weight, highlighting that there are no 'magic' solutions, even with revolutionary GLP-1 drugs.
GLP-1 receptor agonists are revolutionizing obesity treatment by achieving significant and sustainable weight loss through their effects on the central nervous system, as discussed by Professor Stavroula Paschou.
Vivani Medical is innovating a tiny implant containing semaglutide, the active ingredient in popular obesity and diabetes medications, as a new method to help patients sustain weight loss.
India is experiencing a surge of misleading weight-loss products, often identical formulations under different names, on e-commerce platforms, capitalizing on the GLP-1 drug frenzy.
Dr. Mehmet Oz has linked the surge in chronic diseases to obesity, suggesting that GLP-1 medications can serve as a 'jumpstart' for improving health.
Novo Nordisk shares experienced a dip after the latest prescription data indicated a slowdown in the growth of its GLP-1 pill.
Concerns are being raised about the ease of obtaining GLP-1 prescriptions for weight loss online, with some companies reportedly prioritizing 'quick prescriptions' over comprehensive patient care, potentially leading to health risks.
Following the success of GLP-1 agonist medications like Ozempic, many individuals are exploring whether similar effects can be achieved through dietary modifications alone.
A new Medicare GLP-1 Bridge program, effective July 1, will reduce the cost of weight-loss drugs like Wegovy and Zepbound to $50 a month for eligible seniors.
Eli Lilly's stock reached new highs following news of GLP-1 drug inclusion in Medicare and the announcement of significant positive results.
Older adults considering GLP-1 medications for weight loss can now access them for as low as $50 a month. It is important for seniors to understand the implications and eligibility requirements before starting this treatment.
An analysis suggests that Pfizer could be an underrated stock, particularly in the context of its GLP-1 drug development.